Lipocine
LPCN
46 hedge funds and large institutions have $9.54M invested in Lipocine in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 7 closing their positions.
2,478% more call options, than puts
Call options by funds: $928K | Put options by funds: $36K
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
5% more funds holding
Funds holding: 44 → 46 (+2)
0% less ownership
Funds ownership: 0.79% → 0.79% (-0%)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
91% less capital invested
Capital invested by funds: $102M → $9.54M (-$92.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$228K |
| 2 |
Millennium Management
New York
|
+$183K |
| 3 |
Two Sigma Advisers
New York
|
+$153K |
| 4 |
Two Sigma Investments
New York
|
+$90.4K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$901K |
| 2 |
VF
Virtu Financial
New York
|
-$171K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$112K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$57.9K |
| 5 |
Goldman Sachs
New York
|
-$57.4K |
LPCN Hedge Fund Activity: Q2 2022 in Review
46 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2022, worth a combined $9.54M — down 91% from $102M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LPCN positions and 7 closed out — a net gain of 2 holders — while 10 added to existing stakes and 13 trimmed.
The largest buyer was Bridgeway Capital Management, adding an estimated $228K. The largest seller was EAM Investors, exiting entirely with an estimated $901K sold.
- 46 institutional investors held Lipocine (LPCN) as of Q2 2022, up from 44 in Q1 2022.
- Funds reported $9.54M of Lipocine stock for Q2 2022, down 91% quarter-over-quarter.
- 9 funds opened new Lipocine positions in Q2 2022 and 7 closed out, a net change of +2 holders.
- The largest Lipocine buyer in Q2 2022 was Bridgeway Capital Management, an estimated $228K added.
- The largest Lipocine seller in Q2 2022 was EAM Investors, an estimated $901K sold.
Based on aggregated 13F filings for Q2 2022.